Retension Pharmaceuticals (RTSN) IPO deck
Retension Pharmaceuticals is a clinical-stage biopharmaceutical company developing next-generation PDE-5 inhibitors to achieve targeted blood pressure reduction in patients with hypertension.
Retension Pharmaceuticals is a clinical-stage biopharmaceutical company developing next-generation PDE-5 inhibitors to achieve targeted blood pressure reduction in patients with hypertension.
%20IPO%20deck){kind=link}